Tirzepatode Mixing & Dosage Protocols
(Dual GLP-1 & GIP Receptor Agonist for Advanced Weight Management Research)
Reconstitution (Mixing)
- Add 3 ml Bacteriostatic Water to the vial.
- Roll gently between your palms (do not shake).
- Store in the refrigerator after mixing.
Concentration Calculation
30 mg ÷ 3 ml = 10 mg per ml
Every 10 units (0.1 ml) = 1 mg
Dosage Guidelines
For appetite regulation, metabolic balance, and weight-loss research:
- Starting dose: 2.5 mg (≈ 25 units) once per week
-
Titration schedule:
- Weeks 3–4 → 5 mg (50 units) weekly
- Weeks 5–6 → 7.5 mg (75 units) weekly
- Weeks 7–8 → 10 mg (100 units) weekly
- Continue upward only if well-tolerated and required for study outcomes
- Administration: Subcutaneous injection (abdomen, thigh, or upper arm)
- Frequency: Once weekly on the same day
Biopeptics recommendation:
Always start by assessing tolerance with a micro-dose of 2.5 mg, and stay on the lowest effective dose for as long as possible. Some individuals may not need to increase their dosage at all - only adjust the dose if truly necessary, and do so in very small increments.
Key Benefits:
- Enhances insulin sensitivity and metabolic efficiency
- Promotes fat reduction while preserving lean mass
- Improves appetite control, energy stability, and glucose regulation
- Supports cardiovascular health markers in long-term research
Syringe Measurement Guide
|
Dose |
Volume (ml) |
Insulin Units (U-100 Syringe) |
|
1 mg |
0.10 ml |
10 units |
|
2.5 mg |
0.25 ml |
25 units |
|
5 mg |
0.50 ml |
50 units |
|
7.5 mg |
0.75 ml |
75 units |
|
10 mg |
1.00 ml |
100 units |
Each 10 units (0.1 ml) = 1 mg Tirzepatide.
Cycle Duration
Typical research cycle: 12–24 weeks for measurable outcomes.
Maintenance: Continue lowest tolerated dose weekly for ongoing metabolic support.
Important Notes
- Always use sterile needles and alcohol swabs.
- Do not reuse or share needles.
- Store reconstituted vial in the refrigerator (2 – 8 °C).
- For research use only.
- Possible transient effects: mild nausea, fatigue, or injection-site redness; reduce dose if discomfort persists.